Patients were of a median age of 51 years old – 78% with SCC and 22% with adenocarcinoma or adenosquamous carcinoma – and randomised to receive 350mg Libtayo every three weeks or chemotherapy ...

Sanofi and Regeneron have reported new data for Libtayo that suggests the drug could be a contender. Overall survival (OS) was 22 months with the combination, compared to 13 months with chemo on ...

SAN FRANCISCO -- A combination of cemiplimab (Libtayo) and standard-of-care chemotherapy appeared to be effective in patients ...

The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.

Historic benchmarks for either chemotherapy agent alone are 23% ORR ... a clinical trial supply agreement with Regeneron for Libtayo in combination with IMM-1-104 in patients with non-small ...